Rice Partnership LLC Invests $303,000 in Amgen Inc. (NASDAQ:AMGN)

Rice Partnership LLC bought a new position in Amgen Inc. (NASDAQ:AMGN) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 1,162 shares of the medical research company’s stock, valued at approximately $303,000.

Other large investors have also recently made changes to their positions in the company. Capital Performance Advisors LLP bought a new stake in Amgen during the third quarter worth approximately $25,000. Legacy Investment Solutions LLC bought a new stake in Amgen during the third quarter worth approximately $29,000. Matrix Trust Co bought a new stake in Amgen during the third quarter worth approximately $36,000. Heck Capital Advisors LLC bought a new stake in Amgen during the fourth quarter worth approximately $36,000. Finally, Livelsberger Financial Advisory bought a new stake in Amgen during the third quarter worth approximately $56,000. 76.50% of the stock is owned by institutional investors.

Amgen Stock Performance

Shares of AMGN stock opened at $285.42 on Monday. The business’s fifty day simple moving average is $271.06 and its 200-day simple moving average is $304.11. The company has a market cap of $153.42 billion, a PE ratio of 36.55, a PEG ratio of 2.87 and a beta of 0.56. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be given a $2.38 dividend. This represents a $9.52 annualized dividend and a dividend yield of 3.34%. This is an increase from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s dividend payout ratio is presently 115.24%.

Analyst Ratings Changes

Several research analysts have issued reports on AMGN shares. Truist Financial dropped their target price on Amgen from $333.00 to $298.00 and set a “hold” rating for the company in a research report on Wednesday, January 8th. Piper Sandler dropped their target price on Amgen from $344.00 to $310.00 and set an “overweight” rating for the company in a research report on Thursday, January 2nd. William Blair restated an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. Jefferies Financial Group restated a “buy” rating and set a $380.00 target price on shares of Amgen in a research report on Tuesday, November 12th. Finally, StockNews.com lowered Amgen from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $314.00.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.